[HTML][HTML] Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in …

F Chamian, SL Lin, E Lee, T Kikuchi… - Journal of translational …, 2007 - Springer
F Chamian, SL Lin, E Lee, T Kikuchi, P Gilleaudeau, M Sullivan-Whalen, I Cardinale…
Journal of translational medicine, 2007Springer
Abstract Background Alefacept (anti-CD2) biological therapy selectively targets effector
memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease. Methods
Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to
severe psoriasis. Results In all patients, this treatment caused a preferential decrease in
effector memory T cells (CCR7-CD45RA-)(mean 63% reduction) for both CD4+ and CD8+
Tem, while central memory T cells (Tcm)(CCR7+ CD45RA-) were less affected, and naïve T …
Background
Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease.
Methods
Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis.
Results
In all patients, this treatment caused a preferential decrease in effector memory T cells (CCR7- CD45RA-) (mean 63% reduction) for both CD4+ and CD8+ Tem, while central memory T cells (Tcm) (CCR7+CD45RA-) were less affected, and naïve T cells (CCR7+CD45RA+) were relatively spared. Circulating CD8+ effector T cells and Type 1 T cells (IFN-γ-producing) were also significantly reduced.
Conclusion
Alefacept causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
Springer